Replimune Group, Inc. (REPL)
| Market Cap | 212.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -314.85M |
| Shares Out | 82.57M |
| EPS (ttm) | -3.44 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,296,029 |
| Open | 2.650 |
| Previous Close | 2.680 |
| Day's Range | 2.550 - 2.725 |
| 52-Week Range | 1.500 - 13.240 |
| Beta | 0.74 |
| Analysts | Hold |
| Price Target | 5.67 (+120.62%) |
| Earnings Date | May 21, 2026 |
About REPL
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that express an anti-CTLA-4 antibody-like protein to block the i... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for REPL stock is "Hold." The 12-month stock price target is $5.67, which is an increase of 120.62% from the latest price.
News
US Health Secretary Kennedy distances himself from FDA's Replimune cancer drug rejection
Health Secretary Robert F. Kennedy Jr. told a Senate hearing on Wednesday that he had nothing to do with the U.S. FDA's decision to not approve Replimune's drug for advanced skin cancer, saying it w...
FDA Rejection Sparks Questions On Replimune Drug Approval Path
Replimune Group Inc. (NASDAQ: REPL) on Friday received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration for its Biologics License Application.
Replimune co-founder calls FDA rejection of melanoma drug ‘unfair'
Philip Astley-Sparke, executive chairman and co-founder at Replimune, joins ‘Squawk on the Street' to discuss the company's next steps after the FDA denied its melanoma drug.
Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced Melanoma
WOBURN, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno...
US FDA declines to approve Replimune's drug for advanced skin cancer
The U.S. Food and Drug Administration on Friday declined to approve Replimune's drug for advanced skin cancer, the regulator said.
Replimune Group Transcript: Leerink Global Healthcare Conference 2026
The company is preparing for an April 10th PDUFA for its lead asset RP1 in advanced melanoma, with strong physician and patient advocacy support and commercial readiness in place. RP2 and additional indications are advancing, with key data expected by early next year. Cash runway extends into early 2027.
Replimune to Present at Two Upcoming Investor Conferences
WOBURN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno...
Replimune Reports Fiscal Third Quarter 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
Replimune Group Transcript: 44th Annual J.P. Morgan Healthcare Conference
At the JPMorgan Healthcare Conference, Replimune highlighted strong clinical data for its oncolytic immunotherapy, readiness for commercial launch, and robust regulatory progress. The company is expanding its pipeline into new cancer indications and maintains a solid financial position.
Replimune to Present at the 44th Annual J.P. Morgan Healthcare Conference
WOBURN, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
Replimune Presents Late-Breaking Abstract and Additional Posters on RP1 at 40th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC 2025)
Oral presentation of biomarker data shows RP1 plus nivolumab reverses multiple resistance mechanisms to PD-1 blockade in advanced melanoma following definitive anti-PD-1 failure Oral presentation of b...
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
Replimune Announces FDA Acceptance of BLA Resubmission of RP1 for the Treatment of Advanced Melanoma
Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026 Prescription Drug User Fee Act (PDUFA) target action date set for April 10, 2026
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
WOBURN, Mass., Oct. 19, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...
SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options
Replimune Provides Update Following Type A Meeting with FDA
WOBURN, Mass., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno...
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Replimune
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Replimune To Contact Him Directly To Discuss Their Options If you s...
REPL Deadline: REPL Investors with Losses in Excess of $100K Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm
NEW YORK , Sept. 5, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and ...
Replimune Group Transcript: AGM 2025
The meeting covered introductions, legal formalities, and voting on key proposals. Directors were elected, the auditor was ratified, and executive compensation was approved, but the incentive plan amendment did not pass.
REPL Investors Have Opportunity to Lead Replimune Group, Inc. Securities Lawsuit First Filed by The Rosen Law Firm
NEW YORK , Sept. 2, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Replimune Group, Inc. (NASDAQ: REPL) between November 22, 2024 and ...
Replimune Announces Type A Meeting Scheduled with FDA
WOBURN, Mass., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today anno...
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in Replimune Group, Inc. Lawsuit – REPL
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Replimune Group, Inc. (NASDAQ: REPL).
Shareholders who lost money on Replimune Group, Inc. (NASDAQ: REPL) Should Contact Wolf Haldenstein Immediately as Lead Plaintiff Deadline is September 22nd
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed on behalf of all persons or entities who purchased...
Replimune Reports Fiscal First Quarter 2026 Financial Results and Provides Corporate Update
WOBURN, Mass., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today annou...